Ashfield and IPCAA Study Reveals HCPs’ Thoughts On Virtual Congresses
Ashfield and IPCAA join forces to find out what HCPs really think about virtual medical congresses in new global study.
Ashfield Meetings & Events (part of UDG Healthcare PLC) and the International Pharmaceutical Congress Advisory Association (IPCAA) today released a study which reveals what healthcare professionals really think about virtual medical congresses.
Through a survey of more than 300 physicians from six countries (US and EU) and across 14 therapy areas, the global healthcare meetings specialist and the advisory association have gained detailed insights that are set to help medical societies, professional congress organizers (PCOs), and the industry consider how to shape virtual congresses of the future.
The study – the second part of which is planned for before the end of 2020 – looks at a variety of elements of the virtual congress, highlighting HCPs’ thoughts on accessibility and technology, how they viewed the online activities including industry symposia and poster sessions, and connecting with industry and peers.
For a summary report of IPCAA and Ashfield’s initial findings, click here.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
